Diabetes & Metabolism Journal

Ran Choi (Choi R)

1 Article

Effects of Spironolactone and Losartan on Diabetic Nephropathy in a Type 2 Diabetic Rat Model: Mi Young Lee, Myoung Sook Shim, Bo Hwan Kim, Soon Won Hong, Ran Choi, Eun Young Lee, Soo Min Nam, Gun Woo Kim, Jang Yel Shin, Young Goo Shin, Choon Hee Chung; Diabetes Metab J. 2011;35(2):130-137. Published online April 30, 2011; DOI: https://doi.org/10.4093/dmj.2011.35.2.130

4,567 View
66 Download
15 Crossref

Background

While there is an evidence that the anti-inflammatory properties of spironolactone can attenuate proteinuria in type 2 diabetes, its effects on vascular endothelial growth factor (VEGF) expression in diabetic nephropathy have not been clearly defined. In this study, we examined the effects of spironolactone, losartan, and a combination of these two drugs on albuminuria, renal VEGF expression, and inflammatory and oxidative stress markers in a type 2 diabetic rat model.

Methods

Thirty-three Otsuka-Long-Evans-Tokushima-Fatty (OLETF) rats were divided into four groups and treated with different medication regimens from weeks 25 to 50; OLETF diabetic controls (n=5), spironolactone-treated (n=10), losartan-treated (n=9), and combination of spironolactone- and losartan-treated (n=9).

Results

At week 50, the albumin-to-creatinine ratio was significantly decreased in the losartan and combination groups compared to the control OLETF group. No decrease was detected in the spironolactone group. There was a significant reduction in renal VEGF, transforming growth factor (TGF)-β, and type IV collagen mRNA levels in the spironolactone- and combination regimen-treated groups. Twenty-four hour urine monocyte chemotactic protein-1 levels were comparable in all four groups but did show a decreasing trend in the losartan and combination regimen groups. Twenty-four hour urine malondialdehyde levels were significantly decreased in the spironolactone- and combination regimen-treated groups.

Conclusion

These results suggest that losartan alone and a combined regimen of spironolactone and losartan could ameliorate albuninuria by reducing renal VEGF expression. Also, simultaneous treatment with spironolactone and losartan may have protective effects against diabetic nephropathy by decreasing TGF-β and type IV collagen expression and by reducing oxidative stress in a type 2 diabetic rat model.

Citations

Citations to this article as recorded by

Tetrahydrocurcumin Add‐On therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury
Mahyar Khazaeli, Ane C. F. Nunes, Yitong Zhao, Mahziar Khazaali, John Prudente, Nosratola D. Vaziri, Bhupinder Singh, Wei Ling Lau
Pharmacology Research & Perspectives.2023;[Epub] CrossRef
Type 2 Diabetes Mellitus: Pathogenic Features and Experimental Models in Rodents
Inessa G. Gvazava, M. V. Karimova, A. V. Vasiliev, E. A. Vorotelyak
Acta Naturae.2022; 14(3): 57. CrossRef
Role of mineralocorticoid receptor antagonists in kidney diseases
Vishal Patel, Amit Joharapurkar, Mukul Jain
Drug Development Research.2021; 82(3): 341. CrossRef
Multi-strain probiotic supplement attenuates streptozotocin-induced type-2 diabetes by reducing inflammation and β-cell death in rats
Pei-Shan Hsieh, Hsieh-Hsun Ho, Shu Ping Tsao, Shih-Hung Hsieh, Wen-Yang Lin, Jui-Fen Chen, Yi-Wei Kuo, Shin-Yu Tsai, Hui-Yu Huang, Michael W. Greene
PLOS ONE.2021; 16(6): e0251646. CrossRef
Ocular surface complications in diabetes: The interrelationship between insulin and enkephalin
Indira Purushothaman, Ian S. Zagon, Joseph W. Sassani, Patricia J. McLaughlin
Biochemical Pharmacology.2021; 192: 114712. CrossRef
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
Frontiers in Pharmacology.2021;[Epub] CrossRef
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats
Devesh Aggarwal, Gaaminepreet Singh
Naunyn-Schmiedeberg's Archives of Pharmacology.2020; 393(4): 615. CrossRef
Bioactive Agent Discovery from the Natural Compounds for the Treatment of Type 2 Diabetes Rat Model
Shih-Chun Yang, Ching-Yun Hsu, Wei-Ling Chou, Jia-You Fang, Shih-Yi Chuang
Molecules.2020; 25(23): 5713. CrossRef
Losartan improves renal function and pathology in obese ZSF-1 rats
Zhi Su, Deborah Widomski, Arthur Nikkel, Laura Leys, Marian Namovic, Diana Donnelly-Roberts, Murali Gopalakrishnan, Steve McGaraughty
Journal of Basic and Clinical Physiology and Pharmacology.2018; 29(3): 281. CrossRef
Analyzing polymeric nanofibrous scaffold performances in diabetic animal models for translational chronic wound healing research
Nowsheen Goonoo, Archana Bhaw-Luximon
Nanotechnology Reviews.2017; 6(6): 583. CrossRef
Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy
Motonobu Nakamura, Nobuhiko Satoh, Masashi Suzuki, Haruki Kume, Yukio Homma, George Seki, Shoko Horita
Biochemical and Biophysical Research Communications.2015; 461(1): 154. CrossRef
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats
Amal Hofni, Mohamed A. El-Moselhy, Ashraf Taye, Mohamed M. Khalifa
European Journal of Pharmacology.2014; 744: 173. CrossRef
Renal Protective Role of Xiexin Decoction with Multiple Active Ingredients Involves Inhibition of Inflammation through Downregulation of the Nuclear Factor-κB Pathway in Diabetic Rats
Jia-sheng Wu, Rong Shi, Jie Zhong, Xiong Lu, Bing-liang Ma, Tian-ming Wang, Bin Zan, Yue-ming Ma, Neng-neng Cheng, Fu-rong Qiu
Evidence-Based Complementary and Alternative Medicine.2013; 2013: 1. CrossRef
The use of animal models in diabetes research
Aileen JF King
British Journal of Pharmacology.2012; 166(3): 877. CrossRef
Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats
Jae Hee Ahn, Ho Cheol Hong, Myong Jin Cho, Yoon Jung Kim, Hae Yoon Choi, Chai Ryoung Eun, Sae Jeong Yang, Hye Jin Yoo, Hee Young Kim, Ji A Seo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Dong Seop Choi, Nan Hee Kim
Diabetes & Metabolism Journal.2012; 36(2): 128. CrossRef

Author index